APP and Alzheimer disease: Finally, we showed that miRNA mimics AgomiR‐425 oligonucleotide treatment ameliorates pathological and behavior phenotypes in the APP/PS1 AD model, suggesting that modifying brain microenvironment by supplementation of miR‐425 could be a therapeutic strategy for treating AD.